Generics of old GLP-1s could make new versions cheaper
Two of the oldest GLP-1 drugs have recently become available in generic form, potentially paving the way for lower prices on newer brand-name versions like Ozempic and other semaglutide-based medications. This development comes at a crucial time, as Medicare considers expanding coverage to include these drugs for weight loss.
The landscape of GLP-1 medications is evolving rapidly, with the introduction of generics adding a new layer of complexity to pricing and access. Understanding how these changes may impact the cost and availability of current leading treatments is essential for patients, healthcare providers, and policymakers alike.
To delve deeper into this topic and explore the implications of generic GLP-1s on the market, you can access the full article on STAT+ for comprehensive coverage and analysis.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter focusing on the politics and policy of health and medicine. Stay informed by signing up to receive it directly in your inbox on Tuesdays and Thursdays.
